Sept. 24th Deadline Alert: Investors Who Lost More Than $100,000 With MacroGenics, Inc. (NASDAQ:MGNX) Shares Should Contact the Shareholders Foundation
SAN DIEGO, CA, September 11, 2024 (Newswire.com) - The Shareholders Foundation, Inc. announced that September 24, 2024, a deadline is coming up in the lawsuit that was filed for certain investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX). Investors in NASDAQ: MGNX shares should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The Shareholders Foundation, Inc. announced that September 24, 2024, a deadline is coming up in the lawsuit that was filed for certain investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX).
Investors, who purchased shares in excess of $100,000 of MacroGenics, Inc. (NASDAQ: MGNX) between October 7, 2020, and March 19, 2024, have certain options and for certain investors are short and strict deadlines running. Investors in NASDAQ: MGNX shares should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On April 3, 2024, MacroGenics, Inc issued a press release describing a research abstract it submitted about the TAMARACK study.
On May 9, 2024, MacroGenics, Inc released updated safety and efficacy data for its cancer treatment study TAMARACK, which investigates the drug package "Vobra Duo." The Company announced Vobra Duo's adverse event rate was over 99% for both the 2.0 mg/kg and 2.7 mg/kg dosages and that adverse events grade 3 or greater were over 50% for both dosages. Five deaths were linked to the study. Analysts expressed surprise and dismay at the changes in Vobra Duo's safety profile relative to the announcements earlier in the year and questioned management's candor.
On July 26, 2024, an investor in NASDAQ: MGNX shares filed a lawsuit against MacroGenics, Inc. over alleged violations of securities laws. The plaintiff alleges that the defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine.
Those who purchased MacroGenics, Inc. (NASDAQ: MGNX) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Contact Information
Michael Daniels
Manager
mail@shareholdersfoundation.com
858-779-1554
SOURCE: Shareholders Foundation, Inc.
Source: Shareholders Foundation, Inc.
Related Media
